CABA Collar Strategy
CABA (Cabaletta Bio, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris.
CABA (Cabaletta Bio, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $495.7M, a beta of 3.23 versus the broader market, a 52-week range of 1.26-4.23, average daily share volume of 4.2M, a public-listing history dating back to 2019, approximately 161 full-time employees. These structural characteristics shape how CABA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 3.23 indicates CABA has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a collar on CABA?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current CABA snapshot
As of June 29, 2026, spot at $3.10, ATM IV 83.60%, IV rank 16.62%, expected move 23.97%. The collar on CABA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this collar structure on CABA specifically: IV regime affects collar pricing on both sides; compressed CABA IV at 83.60% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 23.97% (roughly $0.74 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CABA expiries trade a higher absolute premium for lower per-day decay. Position sizing on CABA should anchor to the underlying notional of $3.10 per share and to the trader's directional view on CABA stock.
CABA collar setup
The CABA collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CABA near $3.10, the first option leg uses a $3.26 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CABA chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CABA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $3.10 | long |
| Sell 1 | Call | $3.26 | N/A |
| Buy 1 | Put | $2.95 | N/A |
CABA collar risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
CABA collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on CABA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use collar on CABA
Collars on CABA hedge an existing long CABA stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
CABA thesis for this collar
The market-implied 1-standard-deviation range for CABA extends from approximately $2.36 on the downside to $3.84 on the upside. A CABA collar hedges an existing long CABA position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current CABA IV rank near 16.62% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CABA at 83.60%. As a Healthcare name, CABA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CABA-specific events.
CABA collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CABA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CABA alongside the broader basket even when CABA-specific fundamentals are unchanged. Always rebuild the position from current CABA chain quotes before placing a trade.
Frequently asked questions
- What is a collar on CABA?
- A collar on CABA is the collar strategy applied to CABA (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With CABA stock trading near $3.10, the strikes shown on this page are snapped to the nearest listed CABA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CABA collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the CABA collar priced from the end-of-day chain at a 30-day expiry (ATM IV 83.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CABA collar?
- The breakeven for the CABA collar priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CABA market-implied 1-standard-deviation expected move is approximately 23.97%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on CABA?
- Collars on CABA hedge an existing long CABA stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current CABA implied volatility affect this collar?
- CABA ATM IV is at 83.60% with IV rank near 16.62%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.